Want to see HK:1541 full AI Analyst Report?
Total Valuation
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has a market cap or net worth of HK$1.46B. The enterprise value is HK$992.18M.
Market CapHK$1.46B
Enterprise ValueHK$992.18M
Share Statistics
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 420,477,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding420,477,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -21.33%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.19
Return on Invested Capital (ROIC)-21.33%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee744.06K
Profits Per Employee-1.05M
Employee Count202
Asset Turnover0.14
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is ―. ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s PEG ratio is 0.26.
PE Ratio―
PS Ratio14.37
PB Ratio2.73
Price to Fair Value2.73
Price to FCF-10.96
Price to Operating Cash Flow-5.35
PEG Ratio0.26
Income Statement
In the last 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had revenue of 150.30M and earned -212.92M in profits. Earnings per share was -0.51.
Revenue150.30M
Gross Profit134.99M
Operating Income-217.26M
Pretax Income-213.58M
Net Income-212.92M
EBITDA-203.03M
Earnings Per Share (EPS)-0.51
Cash Flow
In the last 12 months, operating cash flow was -232.80M and capital expenditures -1.95M, giving a free cash flow of -234.76M billion.
Operating Cash Flow-232.80M
Free Cash Flow-234.76M
Free Cash Flow per Share-0.56
Dividends & Yields
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-76.87%
50-Day Moving Average3.37
200-Day Moving Average4.29
Relative Strength Index (RSI)50.27
Average Volume (3m)482.23K
Important Dates
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H upcoming earnings date is Mar 30, 2027, Before Open (Confirmed).
Last Earnings DateAug 26, 2026
Next Earnings DateMar 30, 2027
Ex-Dividend Date―
Financial Position
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H as a current ratio of 3.83, with Debt / Equity ratio of 58.02%
Current Ratio3.83
Quick Ratio3.83
Debt to Market Cap0.10
Net Debt to EBITDA2.22
Interest Coverage Ratio-42.05
Taxes
In the past 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has paid 28.25K in taxes.
Income Tax28.25K
Effective Tax Rate>-0.01
Enterprise Valuation
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H EV to EBITDA ratio is -8.41, with an EV/FCF ratio of -8.66.
EV to Sales11.36
EV to EBITDA-8.41
EV to Free Cash Flow-8.66
EV to Operating Cash Flow-8.72
Balance Sheet
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has HK$946.44M in cash and marketable securities with HK$363.12M in debt, giving a net cash position of HK$583.33M billion.
Cash & Marketable SecuritiesHK$946.44M
Total DebtHK$363.12M
Net CashHK$583.33M
Net Cash Per ShareHK$1.39
Tangible Book Value Per ShareHK$1.92
Margins
Gross margin is 94.57%, with operating margin of -144.55%, and net profit margin of -141.66%.
Gross Margin94.57%
Operating Margin-144.55%
Pretax Margin-142.10%
Net Profit Margin-141.66%
EBITDA Margin-135.08%
EBIT Margin-144.55%
Analyst Forecast
The average price target for ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is HK$6.28, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$6.28
Price Target Upside2.11% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast28.93%
EPS Growth Forecast27.27%